CompletedPhase 1NCT04279769
Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Calithera Biosciences, Inc
- Principal Investigator
- Emil T Kuriakose, MDCalithera Bioscience
- Intervention
- CB-280(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2021
Study locations (20)
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Long Beach Memorial Medical Center, Long Beach, California, United States
- University of Florida, Gainesville, Florida, United States
- The Cystic Fibrosis Institute, Glenview, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Boston Children's Hospital, Brigham & Women's Hospital, Boston, Massachusetts, United States
- Billings Clinic, Billings, Montana, United States
- New York Medical College at Westchester Medical Center, Hawthorne, New York, United States
- UNC Marsico Clinical Research Center, Chapel Hill, North Carolina, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Hershey Medical Center Pennsylvania State University, Hershey, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- University of Utah, Salt Lake City, Utah, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04279769 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.